Cargando…
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
BACKGROUND: The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cho...
Autores principales: | Kühnast, Susan, van der Tuin, Sam J.L., van der Hoorn, José W.A., van Klinken, Jan B., Simic, Branko, Pieterman, Elsbet, Havekes, Louis M., Landmesser, Ulf, Lüscher, Thomas F., Willems van Dijk, Ko, Rensen, Patrick C.N., Jukema, J. Wouter, Princen, Hans M.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286319/ https://www.ncbi.nlm.nih.gov/pubmed/25142968 http://dx.doi.org/10.1093/eurheartj/ehu319 |
Ejemplares similares
-
Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol
por: Kühnast, Susan, et al.
Publicado: (2013) -
Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation
por: Inia, José A., et al.
Publicado: (2023) -
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
por: Landlinger, Christine, et al.
Publicado: (2017) -
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
por: Kühnast, Susan, et al.
Publicado: (2014) -
Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice
por: Pouwer, Marianne G., et al.
Publicado: (2020)